
Research Square (Research Square), Год журнала: 2024, Номер unknown
Опубликована: Дек. 18, 2024
Язык: Английский
Research Square (Research Square), Год журнала: 2024, Номер unknown
Опубликована: Дек. 18, 2024
Язык: Английский
CNS Drugs, Год журнала: 2025, Номер unknown
Опубликована: Март 20, 2025
Язык: Английский
Процитировано
1CNS Drugs, Год журнала: 2025, Номер unknown
Опубликована: Март 20, 2025
Narcolepsy is a rare, chronic sleep disorder with significant impacts on the quality of life people affected by disorder. People narcolepsy (PWN) are diverse patient population evolving symptoms, comorbidities, and perspectives. As PWN have varying needs, clinicians should consider more personalized approach to therapy, including active participation in their care shared decision-making between clinician achieve optimal outcomes. In this review, we discuss various characteristics challenges PWN, present illustrative clinical case scenarios provide proposed framework best address therapy for demystify concerns sodium oxybate.
Язык: Английский
Процитировано
1Cell Reports, Год журнала: 2025, Номер 44(2), С. 115277 - 115277
Опубликована: Фев. 1, 2025
Highlights•Ox2R is expressed in distinct molecular sub-populations of MCH neurons•Orexin B elicits excitatory and inhibitory responses neurons•Ox2R inactivation neurons impairs REM sleep female mice•Ox2R insulin sensitivity miceSummaryOrexin/hypocretin receptor type 2 (Ox2R), which widely the brain, receives orexin signals modulates metabolism. Ox2R selective agonists are currently under clinical trials for narcolepsy treatment. Here, we focused on expression function melanin-concentrating hormone (MCH) neurons, have opposite roles to metabolism regulation. Ox2R-expressing showed heterogeneity RNA expression, application brain slices induced both neuron populations. reduced transitions from non-rapid eye movement (NREM) impaired with excessive feeding after a fasting period mice. In conclusion, mediates vivo, regulate mice.Graphical abstract
Язык: Английский
Процитировано
0Computer Methods and Programs in Biomedicine, Год журнала: 2025, Номер 262, С. 108678 - 108678
Опубликована: Фев. 18, 2025
Язык: Английский
Процитировано
0Biomedicines, Год журнала: 2024, Номер 12(12), С. 2772 - 2772
Опубликована: Дек. 5, 2024
Background/Objectives: Comorbid post-traumatic stress disorder (PTSD) and alcohol use (AUD) patients are at a significantly higher risk of adverse outcomes, including opioid disorder, depression, suicidal behaviors, death, yet limited treatment options exist for this population. This study aimed to build on previous research by incorporating drug target information into novel deep learning model, T-DeepBiomarker, predict outcomes identify potential therapeutic medications. Methods: We utilized electronic medical record (EMR) data from the University Pittsburgh Medical Center (UPMC), analyzing 5565 PTSD + AUD patients. T-DeepBiomarker was developed integrating multimodal data, lab results, information, comorbidities, neighborhood-level social determinants health (SDoH), individual-level SDoH (e.g., psychotherapy veteran status). The model trained events, within three months following any clinical encounter. Candidate medications targeting significant proteins were identified through literature reviews. Results: achieved high predictive performance with an AUROC 0.94 in Several medications, OnabotulinumtoxinA, Dronabinol, Acamprosate, Celecoxib, Exenatide, Melatonin, Semaglutide, as potentially reducing events proteins. Conclusions: demonstrates accuracy predicting highlights candidate drugs effects. These findings advance pharmacotherapy high-risk population that warrant further investigation.
Язык: Английский
Процитировано
1Research Square (Research Square), Год журнала: 2024, Номер unknown
Опубликована: Дек. 18, 2024
Язык: Английский
Процитировано
0